NNOX trades 1263.6% below Wall Street's consensus target of $18.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NNOX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 7, 2026, Nano-X Imaging Ltd. (NNOX) has a Wall Street consensus price target of $18.00, based on estimates from 5 covering analysts. With the stock currently trading at $1.32, this represents a potential upside of +1263.6%. The company has a market capitalization of $92M.
Analyst price targets range from a low of $18.00 to a high of $18.00, representing a 0% spread in expectations. The median target of $18.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, NNOX trades at a trailing P/E of -1.1x. Analysts expect EPS to grow +39.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
HOLOMicroCloud Hologram Inc. | $21M | $1.59 | — | — | — | — | — |
ATECAlphatec Holdings, Inc. | $1.4B | $9.33 | $18.00 | +92.9% | Buy | 29.2x | 18 |
PRCTPROCEPT BioRobotics Corporation | $1.2B | $21.21 | $31.60 | +49.0% | Buy | — | 15 |
GEHCGE HealthCare Technologies Inc. | $29.5B | $64.84 | $81.00 | +24.9% | Buy | 13.3x | 18 |
SYKStryker Corporation | $120.1B | $313.38 | $387.46 | +23.6% | Buy | 20.9x | 51 |
ISRGIntuitive Surgical, Inc. | $153.3B | $432.83 | $597.78 | +38.1% | Buy | 41.4x | 55 |
MMSIMerit Medical Systems, Inc. | $4.3B | $71.45 | $94.20 | +31.8% | Buy | 17.6x | 14 |
MDTMedtronic plc | $106.6B | $83.06 | $95.80 | +15.3% | Buy | 13.9x | 51 |
BSXBoston Scientific Corporation | $66.3B | $44.60 | $82.40 | +84.8% | Buy | 13.3x | 44 |
PHGKoninklijke Philips N.V. | $26.8B | $28.16 | — | — | Hold | 18.1x | 22 |
Quick answers to the most common questions about buying NNOX stock.
The consensus Wall Street price target for NNOX is $18, representing 1263.6% upside from the current price of $1.32. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
NNOX has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $18 implies 1263.6% upside from current levels.
NNOX's current price is $1.32 with a consensus target of $18 (1263.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $18 for NNOX, while the most conservative target is $18. The consensus of $18 represents the median expectation. These targets typically reflect 12-month expectations.
NNOX is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NNOX stock forecast based on 5 Wall Street analysts shows a consensus price target of $18, with estimates ranging from $18 (bear case) to $18 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on NNOX, with a "Buy" consensus rating and $18 price target (1263.6% upside). 4 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NNOX analyst price targets range from $18 to $18, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $18 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.